During the past decade, Premiere Research Institute conducted 51 clinical trials. In the 10-year time frame, 51 clinical trials started and 43 clinical trials were completed, i.e. on average, 84.3% percent of trials that started reached the finish line to date. In the past 5 years, 26 clinical trials started and 20 clinical trials were completed. i.e. 76.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Premiere Research Institute" #1 sponsor was "Eli Lilly and Company" with 10 trials, followed by "Pfizer" with 9 trials sponsored, "Allergan" with 6 trials sponsored, "Amgen" with 4 trials sponsored and "Athira Pharma" with 4 trials sponsored. Other sponsors include 58 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Premiere Research Institute" #1 collaborator was "National Institute on Aging (NIA)" with 5 trials as a collaborator, "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 4 trials as a collaborator, "Alzheimer's Disease Cooperative Study (ADCS)" with 3 trials as a collaborator, "Alzheimer's Therapeutic Research Institute" with 3 trials as a collaborator and "Northern California Institute of Research and Education" with 3 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "Premiere Research Institute" are "Alzheimer's Disease" (31 trials), "Alzheimer Disease" (21 trials), "Migraine" (14 trials), "Mild Cognitive Impairment" (4 trials) and "Dementia" (3 trials). Many other conditions were trialed in "Premiere Research Institute" in a lesser frequency.

Most popular intervention types in "Premiere Research Institute" are "Drug" (84 trials), "Other" (8 trials), "Biological" (7 trials), "Device" (5 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (39 trials), "ATH-1017" (4 trials), "Donepezil" (4 trials), "Galcanezumab" (3 trials) and "Lasmiditan" (3 trials). Other intervention names were less common.

The vast majority of trials in "Premiere Research Institute" are 96 trials for "All" genders.

Currently, there are NaN active trials in "Premiere Research Institute". undefined are not yet recruiting, 9 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 60 completed trials in Premiere Research Institute, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Premiere Research Institute, 4 "Phase 1" clinical trials were conducted, 37 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 3 trials that are defined as “Not Applicable".